NCT06413953View on ClinicalTrials.gov

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Cancers
Interventions
DRUG

TQB3107 Tablets

TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Cen, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY